Lipocine Inc. (NASDAQ:LPCN) Sees Significant Decrease in Short Interest

Lipocine Inc. (NASDAQ:LPCN) was the target of a significant decline in short interest in the month of May. As of May 15th, there was short interest totaling 102,133 shares, a decline of 41.2% from the April 30th total of 173,716 shares. Based on an average daily trading volume, of 103,762 shares, the short-interest ratio is presently 1.0 days. Currently, 1.3% of the shares of the company are sold short.

Lipocine Stock Performance

Shares of NASDAQ:LPCN traded up $0.01 during trading hours on Thursday, reaching $2.20. The stock had a trading volume of 29,405 shares, compared to its average volume of 290,534. Lipocine has a 1 year low of $1.81 and a 1 year high of $12.37. The firm’s 50 day moving average is $3.05 and its 200-day moving average is $5.61. The stock has a market capitalization of $18.09 million, a price-to-earnings ratio of -1.17 and a beta of 0.48.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.16 million. Lipocine had a negative return on equity of 66.70% and a negative net margin of 571.18%. Analysts forecast that Lipocine will post -1.91 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Wall Street Zen lowered shares of Lipocine from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. HC Wainwright reiterated a “neutral” rating on shares of Lipocine in a report on Monday, April 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lipocine in a report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $15.00.

Insider Buying and Selling at Lipocine

In other news, CEO Mahesh V. Patel acquired 25,000 shares of the business’s stock in a transaction on Monday, April 6th. The stock was bought at an average price of $2.03 per share, with a total value of $50,750.00. Following the completion of the acquisition, the chief executive officer owned 160,679 shares of the company’s stock, valued at approximately $326,178.37. This represents a 18.43% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director John W. Higuchi acquired 40,000 shares of the business’s stock in a transaction on Tuesday, April 7th. The stock was purchased at an average cost of $2.03 per share, with a total value of $81,200.00. Following the acquisition, the director directly owned 203,797 shares of the company’s stock, valued at $413,707.91. This represents a 24.42% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 213,000 shares of company stock valued at $434,600 over the last quarter. Insiders own 6.35% of the company’s stock.

Hedge Funds Weigh In On Lipocine

Several hedge funds have recently added to or reduced their stakes in LPCN. Squadron Capital Management LLC purchased a new position in Lipocine during the 4th quarter valued at about $4,256,000. Eversept Partners LP purchased a new position in Lipocine during the 1st quarter valued at about $2,357,000. Diadema Partners LP purchased a new position in Lipocine during the 4th quarter valued at about $2,095,000. AIGH Capital Management LLC purchased a new position in Lipocine during the 1st quarter valued at about $1,598,000. Finally, Ikarian Capital LLC purchased a new position in Lipocine during the 4th quarter valued at about $1,602,000. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.